Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 30, 2026

Toobit 2026 H1 Review: TradFi, Futures, & AI Trading Upgrades

View original at globenewswire.com
Toobit 2026 H1 Review: TradFi, Futures, & AI Trading Upgrades GEORGE TOWN, Cayman Islands, June 30, 2026 (GLOBE NEWSWIRE) -- The first half of 2026 for Toobit has been defined by a focus on building products that help traders navigate markets…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Toobit achieved an AAA security rating, placing it among the top 10 most secure crypto exchanges globally, with perfect 100/100 scores in server security, user security, penetration testing, and bug bounty management

    60% confidence

  • As Toobit enters the second half of 2026, the focus shifts toward expanding the TradFi portfolio and scaling AI-assisted trading tools

    60% confidence

  • Toobit captured a top 10 position globally per the CoinGecko 2026 CEX & DEX Trading Report, demonstrating deep liquidity and high user engagement across spot and perps markets

    60% confidence

  • Hacken's audit confirmed a collateral ratio exceeding 100% across all in-scope digital assets

    60% confidence

  • Toobit was named Digital Asset Derivatives Platform of the Year for the second consecutive year following a rigorous selection process combining expert panel vetting with extensive industry voting

    60% confidence

Data points we hold from this source

XRP · earn apr offered30 percent
Bitcoin · earn apr offered30 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Toobit 2026 H1 Review: TradFi, Futures, & AI Trading Upgrades — Source | Via News | ViaNews Market